International Journal of Obesity, 34(S1), S47 to S55
This is actually one argument in favor of microdosing , where gastrointestinal effects are minimized while anti-inflammatory receptor activation may still occur
Most patients move through several key phases when adjusting to their maintenance dose: Assessing Your Current State: When youve reached the weight you want to maintain, even if youre still losing, its a good time to talk with your healthcare team about transitioning to a maintenance dose
GLP-1 infusion increases natriuresis by reducing tubular sodium reabsorption and reduces hyperfiltration in obese subjects.50 Chronic treatment with arGLP-1 in patients with DM2 has shown no effect on measured GFR and effective renal plasma flow in the fasting or postprandial state, however it maintains its natriuretic effect.51 GLP-1 and its agonists induce natriuresis by inhibition of the Na+/H + exchanger type 3 in the proximal tubule, although interactions with the renin, insulin, or glucagon system cannot be excluded5254 because they reduce circulating levels of RAS components51,5355 (Fig
Increased Risk of Eye Infections: Some people who take Wegovy may also have diabetes
